It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hexokinase 2 (HK2), which catalyzes the first committed step in glucose metabolism, is induced in cancer cells. HK2’s role in tumorigenesis has been attributed to its glucose kinase activity. Here, we describe a kinase independent HK2 activity, which contributes to metastasis. HK2 binds and sequesters glycogen synthase kinase 3 (GSK3) and acts as a scaffold forming a ternary complex with the regulatory subunit of protein kinase A (PRKAR1a) and GSK3β to facilitate GSK3β phosphorylation and inhibition by PKA. Thus, HK2 functions as an A-kinase anchoring protein (AKAP). Phosphorylation by GSK3β targets proteins for degradation. Consistently, HK2 increases the level and stability of GSK3 targets, MCL1, NRF2, and particularly SNAIL. In addition to GSK3 inhibition, HK2 kinase activity mediates SNAIL glycosylation, which prohibits its phosphorylation by GSK3. Finally, in mouse models of breast cancer metastasis, HK2 deficiency decreases SNAIL protein levels and inhibits SNAIL-mediated epithelial mesenchymal transition and metastasis.
Hexokinase 2 expression is markedly induced in cancer cells and contributes to cancer cell metabolism. Here, the authors show that hexokinase 2 can contribute to the metastatic spread of cancer cells independently of its glycolytic function via inhibiting the activity of GSK3β, which in turn elevates the protein levels of the EMT transcription factor SNAIL.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Illinois at Chicago, Department of Biochemistry and Molecular Genetics, College of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
2 Ajou University Yeongtong-gu, College of Pharmacy, Suwon-si, Korea (GRID:grid.251916.8) (ISNI:0000 0004 0532 3933)
3 University of Illinois at Chicago, Department of Biochemistry and Molecular Genetics, College of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); University of Cincinnati, Department of Cancer Biology, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593)
4 Veterans Affairs Medical Center, White River Junction, Hartford, USA (GRID:grid.413726.5) (ISNI:0000 0004 0420 6436); Geisel School of Medicine at Dartmouth, Hanover, USA (GRID:grid.254880.3) (ISNI:0000 0001 2179 2404)
5 University of Illinois at Chicago, Department of Biochemistry and Molecular Genetics, College of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); Jesse Brown VA Medical Center, Research & Development Section, Chicago, USA (GRID:grid.280892.9) (ISNI:0000 0004 0419 4711)